Clene
Market cap $46.4M 14.4M shares (10-Q, Nov 2, 2026) × $3.22 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- CLNN filingNov 2026CLNN filing, Nov 2026, notable
- Clene financials corporate updateNov 2026Clene financials corporate update, Nov 2026, routine
- RESTORE-ALS Phase 3 Ph3 start2Q 2027RESTORE-ALS Phase 3 Ph3 start, 2Q 2027, routine
- 2024 SSCP Notes corporate updateAug 13, 20272024 SSCP Notes corporate update, Aug 13, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
CNM-ZnAg
- Undisclosed indication
CNM-AgZn17
- Undisclosed indication
Technology platforms
CSN
Clean-surfaced nanotechnology (CSN) electro-crystal-chemistry platform producing catalytically-active, faceted nanocrystals and ionic solutions from transition elements. Enables development of nanotherapeutics targeting cellular energy impairments in neurodegenerative and other diseases. Flexible and tunable — can produce gold, gold-platinum, and other elemental or composite nanocrystals, plus ionic solutions of silver, zinc, and other transition elements.
Targets: NAD+, mitochondrial dysfunction, reactive oxygen species
electro-crystal-chemistry
Electro-crystal-chemistry drug development platform enabling production of concentrated, stable, highly active, clean-surfaced nanocrystal suspensions; focus on central nervous system disorders including ALS, MS, and Parkinson's disease
Capital (as filed)
- Cash
- $9.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$4.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $9.9M cash, runway mid-first quarter 2027 per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-09-16 424B5 · Priced offering 1.22M shares · at $3.28 · $4.0M gross · 18.4% below the prior close ($4.02, Sep 15, 2026)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (15)
- 2026-11-05 UPDATE: Clene Inc. (CLNN) - The Checkpoint Arrives, and the $22M Shrinks 🔒 Paid
- 2026-10-20 UPDATE: Clene Inc. (CLNN) - The Form Is Filed. Now the FDA Decides Whether to Read It. 🔒 Paid
- 2026-09-16 UPDATE: Clene Inc. (CLNN) - The Insiders Wrote the Check Themselves 🔒 Paid
- 2026-08-15 UPDATE: Clene Inc. (CLNN) - A New Name Shows Up on the Cap Table 🔒 Paid
- 2026-08-12 UPDATE: Clene Inc. (CLNN) - The 14.8% Holder Just Went to Zero 🔒 Paid
- 2026-08-11 UPDATE: Clene Inc. (CLNN) - Clene Did the FDA’s Homework. The Tape Hasn’t Noticed. 🔒 Paid
- 2026-05-15 UPDATE: Clene Inc. (CLNN) – The Q1 10-Q Answers Three Questions I Left Open 🔒 Paid
- 2026-05-05 UPDATE: Clene Inc. (CLNN) - The Raise-Into-Strength Trade, Same Day 🔒 Paid
- 2026-05-04 UPDATE: Clene Inc. (CLNN) – The Tofersen Precedent Just Landed
- 2026-03-21 UPDATE: Clene Inc. (CLNN) – The Hidden Catalyst of Non-Dilutive Funding 🔒 Paid
- 2026-03-14 UPDATE: Clene Inc. (CLNN) – 2025 Earnings Confirm the Dilution Thesis and the Timeline 🔒 Paid
- 2026-02-28 UPDATE: Clene Inc. (CLNN) – The FDA Showdown Officially Gets a Timeline 🔒 Paid
- 2026-01-13 UPDATE: Clene Inc. (CLNN) – A Sell the News Moment & The Science Behind It 🔒 Paid
- 2026-01-12 UPDATE: Clene Inc. (CLNN) – The Dilution Gap Is Effectively Gone for 12-Months. Now It’s Just Science 🔒 Paid
- 2025-12-30 Clene Inc (CLNN): Scientific Due Diligence for CNM-Au8 and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (15 calls)
Every verdict Biotech Distilled has published on Clene, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2025-12-30 Watch Clene Inc (CLNN): Scientific Due Diligence for CNM-Au8 and Pipeline Products The dilution gap makes CLNN uninvestable for conservative capital; wait for financing to clear or FDA meeting outcome to de-risk the regulatory path before entering.
- 2026-01-12 Speculative buy speculative UPDATE: Clene Inc. (CLNN) – The Dilution Gap Is Effectively Gone for 12-Months. Now It's Just Science The $28M raise removes the immediate insolvency risk, leaving the thesis purely about the FDA regulatory outcome on the Tofersen Precedent and survival signal.
- 2026-01-13 Speculative buy speculative UPDATE: Clene Inc. (CLNN) – A Sell the News Moment & The Science Behind It The ~19% post-financing drop is sell-the-news noise, not a verdict on the science; the biomarker-to-survival linkage data is the strongest argument yet for the Tofersen Precedent.
- 2026-02-28 Speculative buy speculative UPDATE: Clene Inc. (CLNN) – The FDA Showdown Officially Gets a Timeline Runway is secure through the FDA meeting and NDA submission, the catalyst calendar is hard-coded, and the stock is climbing out of its post-dilution basement.
- 2026-03-14 Speculative buy speculative UPDATE: Clene Inc. (CLNN) – 2025 Earnings Confirm the Dilution Thesis and the Timeline Earnings confirm no delays or surprise expenses; cash is secured for the near term and the FDA meeting is days away, keeping the thesis intact.
- 2026-03-21 Speculative buy speculative UPDATE: Clene Inc. (CLNN) – The Hidden Catalyst of Non-Dilutive Funding An $8M NIH subaward provides non-dilutive funding for the EAP data the FDA is reviewing, and the pivotal Type C meeting is imminent.
- 2026-05-04 Buy core UPDATE: Clene Inc. (CLNN) – The Tofersen Precedent Just Landed The FDA confirmed in writing that NfL could serve as a surrogate endpoint and that the data may support an accelerated-approval NDA, retiring the single biggest regulatory risk in the thesis.
- 2026-05-05 Hold UPDATE: Clene Inc. (CLNN) - The Raise-Into-Strength Trade, Same Day The regulatory thesis is intact but the 18.7% post-offering drop and dilution tax argue for patience; the next catalyst is 4–5 months out creating dead-money risk.
- 2026-05-15 Buy core UPDATE: Clene Inc. (CLNN) – The Q1 10-Q Answers Three Questions I Left Open Debt maturity pushed to August 2027, SymBiosis identified as a 14.8% healthcare-dedicated holder, and runway extended into Q4 2026/2027 on NDA acceptance, improving the financial path to the regulatory finish line.
- 2026-08-11 Buy core UPDATE: Clene Inc. (CLNN) - Clene Did the FDA's Homework. The Tape Hasn't Noticed. The randomization-anchored principal stratum analysis (HR 0.593, p=0.026) with four null negative controls materially strengthens the survival signal, even as the stock has bled 27% during the dead-money window.
- 2026-08-12 Hold UPDATE: Clene Inc. (CLNN) - The 14.8% Holder Just Went to Zero SymBiosis's reported stake dropped to 0% on a manager transfer, creating ambiguity about whether 1.9M shares are a potential supply overhang; science is unchanged but the ownership base is less legible.
- 2026-08-15 Buy core UPDATE: Clene Inc. (CLNN) - A New Name Shows Up on the Cap Table Q2 cash of $9.7M with runway through late Q4 2026 and Vivo Opportunity surfacing at 9.99% (entirely in approval-contingent warrants) partially resolves the anchor-holder ambiguity and loosens the cash-wall collision.
- 2026-09-16 Hold UPDATE: Clene Inc. (CLNN) - The Insiders Wrote the Check Themselves A $4M raise at a 21% discount funded solely by insiders with no outside bid signals deteriorating access to institutional capital, warranting patience into the early-Q4 NDA filing rather than adding.
- 2026-10-20 Hold UPDATE: Clene Inc. (CLNN) - The Form Is Filed. Now the FDA Decides Whether to Read It. NDA submitted on schedule but acceptance-linked warrants are underwater and runway ends mid-Q1 2027; patience until the FDA filing decision in December is the prudent posture.
- 2026-11-05 Hold UPDATE: Clene Inc. (CLNN) - The Checkpoint Arrives, and the $22M Shrinks The acceptance-linked cash has shrunk from ~$22M to $6.7–7.8M (and only arrives if the stock clears $6), while $15.4M of debt service now falls inside the next twelve months against $9.9M cash.
- Long call · opened Jan 12, 2026 at $5.18 · -37.8% vs XBI +17.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Recent Developments of Our Clinical Programs Amyotrophic Lateral Sclerosis In August 2026, we announced the results from new biomarker analyses examining clinical outcomes among CNM-Au8®-treated patients in our two completed Phase 2 ALS trials.”
matched to CNM-Au8 (ALS) · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (34)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 4, 2026ReleaseClene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights→ BD updateSummary on the 8-K
- Nov 4, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateThe Q3 10-Q reveals $9.9M cash, a ~$13M current debt wall, a fresh $7.2M NIH subaward, and management's first explicit disclosure that NDA acceptance could trigger $6.7M–$7.8M in warrant cash — all landing the same morning the stock jumped +8.8%.
- Nov 4, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 20, 20268-KCurrent report: material agreement
- Oct 19, 2026ReleaseClene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS→ BD updateSummary on the 8-K
- Oct 19, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1→ BD updateThe CNM-Au8 NDA is officially submitted to the FDA under the Subpart H accelerated approval pathway — the drawing date on the lottery ticket just became real, and the ~$22M milestone tranches are now in play.BD extracted 1 program update from this document → CLNN pipeline
- Sep 22, 2026ReleaseClene to Present at Upcoming Investor Conferencesvia aggregator
- Sep 21, 2026ReleaseClene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
- Sep 16, 20268-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- Sep 16, 2026424B5Prospectus supplement (offering)
- Sep 15, 2026ReleaseClene Announces $4 Million Registered Direct Offering→ BD updateClene's Chairman, CEO, and founding investor just led a $4M raise at $3.28 — the lowest price yet — buying the company to mid-Q1 2027 while the NDA filing window opens. Insider participation is a real signal; the price and size are a real warning.
- Sep 3, 2026ReleaseClene to Present at Upcoming September Investor Conferences
- Aug 17, 2026ReleaseClene to Present at the Emerging Growth Conference
- Aug 14, 2026ReleaseClene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
- Aug 14, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CLNN pipeline
- Aug 14, 202610-QQuarterly report
- Aug 10, 2026ReleaseClene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
- Aug 10, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CLNN pipeline
- Jul 29, 2026ReleaseClene to Present at The Canaccord 46th Annual Growth Conference
- May 22, 20268-KCurrent report: material agreement, officer / director change, shareholder vote
- May 14, 2026ReleaseClene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
- May 14, 20268-KCurrent report: material agreement, results of operations · EX-99.1 EXHIBIT 99.1
- May 14, 202610-QQuarterly report
- May 5, 2026ReleaseClene to Present at Upcoming May Conferences
- May 5, 2026ReleaseClene Announces $7 Million Underwritten Offering of Common Stock
- May 5, 20268-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- May 5, 2026424B5Prospectus supplement (offering)
- May 5, 2026424B5Prospectus supplement (offering)
- May 4, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Apr 10, 2026DEFA14AProxy soliciting material
- Apr 10, 2026DEF 14AProxy statement
- Mar 17, 20268-KCurrent report: material agreement
- Mar 17, 202610-KAnnual report
- Mar 12, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Oct 13, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 11, 2026SCHEDULE 13G/A13G amendment
- Aug 4, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 5, 2026S-8Employee plan registration
- May 22, 2026SDSpecialized disclosure
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 14, 2026SCHEDULE 13G/A13G amendment
- May 14, 2026SCHEDULE 13G/A13G amendment
- May 12, 2026SCHEDULE 13G/A13G amendment
- Apr 10, 2026ARSAnnual report to shareholders